PodParley PodParley
PodParley
Should Metabolic Imaging to Assess Minimal Residual Disease (MRD) Become a Clinical Endpoint in Multiple Myeloma? episode artwork

EPISODE · Jul 7, 2017 · 14 MIN

Should Metabolic Imaging to Assess Minimal Residual Disease (MRD) Become a Clinical Endpoint in Multiple Myeloma?

from Journal of Clinical Oncology (JCO) Podcast · host Jesus F. San Miguel

Normalization of PET-CT is a strong predictor   for progression free survival (PFS) and overall survival (OS) in multiple myeloma (MM) Related Article: Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study

Episode metadata supplied by the publisher feed · Published Jul 7, 2017

Embed this episode

NOW PLAYING

Should Metabolic Imaging to Assess Minimal Residual Disease (MRD) Become a Clinical Endpoint in Multiple Myeloma?

0:00 14:21

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Journal of Clinical Oncology (JCO) Podcast?

This episode is 14 minutes long.

When was this Journal of Clinical Oncology (JCO) Podcast episode published?

This episode was published on July 7, 2017.

Can I download this Journal of Clinical Oncology (JCO) Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!